Efficacy and safety of pravastatin in the treatment of patients with type I or type II diabetes mellitus and hypercholesterolemia. (Q51585470)

7 April 2018

title

Efficacy and safety of pravastatin in the treatment of patients with type I or type II diabetes mellitus and hypercholesterolemia. (English)

1 reference

7 April 2018

0 references

0 references

0 references

Raskin P

1

1 reference

7 April 2018

Ganda OP

2

1 reference

7 April 2018

Schwartz S

3

1 reference

7 April 2018

Willard D

4

1 reference

7 April 2018

Rosenstock J

5

1 reference

7 April 2018

Lodewick PA

6

1 reference

7 April 2018

Cressman MD

7

1 reference

7 April 2018

Phillipson B

8

1 reference

7 April 2018

Weiner B

9

1 reference

7 April 2018

McGovern ME

10

1 reference

7 April 2018

language of work or name

English

0 references

publication date

1 October 1995

1 reference

7 April 2018

American Journal of Medicine

published in

1 reference

7 April 2018

volume

99

1 reference

7 April 2018

page(s)

362-369

1 reference

7 April 2018

issue

4

1 reference

7 April 2018

Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980182-X

Diabetes and Glucose Tolerance as Risk Factors for Cardiovascular Disease: The Framingham Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980182-X

Lipids, diabetes, and coronary heart disease: insights from the Framingham Study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980182-X

Type 2 (non-insulin-dependent) diabetes mellitus and cardiovascular disease--putative association via common antecedents; further evidence from the Whitehall Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980182-X

Trends in prevalence of diabetes mellitus in patients with myocardial infarction and effect of diabetes on survival. The Minnesota Heart Survey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980182-X

Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980182-X

Plasma lipids and diabetes mellitus in an adult community

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980182-X

Lipoprotein composition in individuals with impaired glucose tolerance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980182-X

Lack of Awareness and Treatment of Hyperlipidemia in Type II Diabetes in a Community Survey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980182-X

Lipoprotein physiology in nondiabetic and diabetic states. Relationship to atherogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980182-X

Lipid-lowering therapy and macrovascular disease in diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980182-X

Detection and management of lipid disorders in diabetic patients. A commentary for clinicians

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980182-X

Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. II. Once-daily versus twice-daily dosing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980182-X

Once-daily pravastatin in patients with primary hypercholesterolemia: a dose-response study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980182-X

A comparison of methods for the estimation of plasma low- and very low-density lipoprotein cholesterol. The Lipid Research Clinics Prevalence Study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980182-X

Effects of lovastatin in diabetic patients treated with chlorpropamide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980182-X

Effect of pravastatin on serum lipids, apolipoproteins and lipoprotein (a) in patients with non-insulin dependent diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980182-X

A multinational study of the effects of low-dose pravastatin in patients with non-insulin-dependent diabetes mellitus and hypercholesterolemia. Pravastatin Multinational Study Group for Diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980182-X

Severity of coronary artery disease in young patients with insulin-dependent diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980182-X

Diabetes mellitus and hypertension in the elderly: concomitant hyperlipidemia and coronary heart disease risk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980182-X

Long-term complications of diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980182-X

Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. The Pravastatin Multinational Study Group for Cardiac Risk Patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980182-X

The effects of lipid lowering on diabetic retinopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980182-X

Decreased Albuminuria by Pravastatin in Hyperlipidemic Diabetics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980182-X

Treatment of hyperlipidemia in the nephrotic syndrome: the effects of pravastatin therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980182-X

Management of dyslipidemia in NIDDM.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980182-X

Management of dyslipidemia in IDDM patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980182-X

10.1016/S0002-9343(99)80182-X

7 January 2021

Identifiers

DOI

1 reference

7 April 2018

PubMed ID

7573090

1 reference

7 April 2018